c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer
Authors
Keywords
Colorectal cancer, Prognosis, Metastasis, Metastatic tumors, Gene amplification, Hyperexpression techniques, Oncology, Silver
Journal
PLoS One
Volume 10, Issue 10, Pages e0139727
Publisher
Public Library of Science (PLoS)
Online
2015-10-02
DOI
10.1371/journal.pone.0139727
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
- (2014) A N Seo et al. BRITISH JOURNAL OF CANCER
- Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status
- (2014) Jung Ho Kim et al. Korean Journal of Pathology
- Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer
- (2014) Christopher W. Toon et al. PLoS One
- KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
- (2013) A I Phipps et al. BRITISH JOURNAL OF CANCER
- 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy
- (2013) Gaelle Fromont et al. HUMAN PATHOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptional Amplification in Tumor Cells with Elevated c-Myc
- (2012) Charles Y. Lin et al. CELL
- Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
- (2011) Jin Hyun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Regulation of gene transcription by the oncoprotein MYC
- (2011) Bernhard Lüscher et al. GENE
- Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma
- (2011) Sung Lee et al. VIRCHOWS ARCHIV
- Mechanisms of MYC stabilization in human malignancies
- (2010) Melissa R. Junttila et al. CELL CYCLE
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- The Cell Cycle and Myc Intersect with Mechanisms that Regulate Pluripotency and Reprogramming
- (2009) Amar M. Singh et al. Cell Stem Cell
- Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study
- (2009) Kathleen M. Darcy et al. GYNECOLOGIC ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation